Autopsy report · NCT03113071

Safety and Activity of Digoxin With Decitabine in Adult AML and MDS

Cause of deathSlow enrollment Automatic label, confidence 0.9, unverified. How labels are made.

“Slow accrual”

The sponsor’s own words in the registry.

Life of this trial

Registered 2 months before it started.
Ran for about 1 year 9 months before it stopped.
1 participant enrolled.
Results were posted on the registry 2 years after it ended.

Vital statistics

Status: Terminated
Phase: Phase 1, Phase 2
Sponsor: Fox Chase Cancer Center
Sponsor type: University, hospital or other
Conditions: Acute Myeloid Leukemia; Myelodysplastic Syndromes
Interventions: Decitabine; Digoxin
Participants: 1
Sites: 2
Countries: United States

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.